MedPath

Fatigue in Systemic Lupus Erythematosus

Completed
Conditions
Fatigue
Systemic Lupus Erthematosus
Registration Number
NCT06652256
Lead Sponsor
Pamukkale University
Brief Summary

The aim of this study is to investigate the effects of biopsychosocial status, quality of life, functional status and hematological markers on fatigue in individuals with SLE.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
39
Inclusion Criteria
  • Being diagnosed with SLE according to the 2019 ACR/EULAR diagnostic criteria
  • Being 18 years of age or older
Exclusion Criteria
  • Not being able to speak or understand Turkish fluently
  • Having a psychiatric illness that will affect cooperation
  • Heart failure or lung pathology that will affect daily life activities
  • Additional autoimmune disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fatigue Assesment ScaleEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

It is a scale consisting 10 items. The maximum score is 50. High score indicates high fatigue.

FACIT Fatigue ScaleEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

It is scale consisting 13 items. Scores range from 0-52. High score indicates low fatigue

Secondary Outcome Measures
NameTimeMethod
Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (BETY-BQ)Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

It is a scale consist of 30 items. Scores range from 0-120. Higher scores indicate worse biopsychosocial status.

Short Form 36 (SF-36) Health SurveyEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

The SF-36 consists of two dimensions, generating a profile of health-related quality of life.These dimensions are: physical health and mental health. Higher scores indicate better health.

HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

The scale consists of 20 questions and includes 8 activities. The total score is obtained by summing the points earned from 8 activities and then dividing that sum by 8. Higher scores indicate worse functional status

Routine blood test resultsEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

Participants' routine blood test results such as neutrophil (NEU (K/uL)) , monocyte (MONO (K/uL)), eosinophil (EO (K/uL)), leukocyte (WBC (K/uL)), lymphocyte (LYM (K/uL)), platelet (PLT (K/uL)) will be recorded.

Routine Blood Test ResultsEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

Sedimentation (mm/h) will be recorded.

Hematological indicesEvaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.

Neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR), platelet\*neutrophil/lymphocyte (systemic inflammatory index), monocyte/platelet (MTO), neutrophil\*monocyte/lymphocyte (systemic inflammatory response index), neutrophil\*monocyte\*platelet/lymphocyte (systemic inflammation aggregate index) obtained from complete blood counts will be calculated and recorded.

Trial Locations

Locations (1)

Pamukkale University

🇹🇷

Denizli, Turkey

© Copyright 2025. All Rights Reserved by MedPath